Lilly - TechWire

Lilly

2025.09.24

01:03

Eli Lilly plans $6.5 billion plant in Texas

Eli Lilly plans to invest $6.5 billion to build a new plant in Texas to produce raw materials for pharmaceuticals, creating 4,615 manufacturing and construction jobs.

01:01

Eli Lilly (LLY.N) plans to build a new $6.5 billion facility in Texas to produce active pharmaceutical ingredients, creating 4,615 manufacturing and construction jobs. The site is expected to be operational within five years.

2025.09.18

17:20

Novo Nordisk's US stock price rose nearly 5% in pre-market trading

Novo Nordisk's US stock rose nearly 5% in pre-market trading. Novo Nordisk's product director said semaglutide has significant advantages over rival Eli Lilly's obesity drug.

14:58

Morgan Stanley: Eli Lilly's oral weight loss drug clinical trial data is impressive, maintaining target price at $1,028

Morgan Stanley's research report stated that Eli Lilly's oral GLP-1 receptor agonist Orfor has performed well in weight loss, improvement of cardiovascular metabolic indicators and safety. The newly released data has not changed its positive view on Orfor's prospects. It maintains an "overweight" rating and a target price of US$1,028 in the next 12 months.

2025.09.16

22:48

Eli Lilly plans $5 billion manufacturing facility in Virginia

On September 16, local time, Eli Lilly and Company announced plans to build a $5 billion manufacturing facility in Goochland County, west of Richmond, Virginia. The new site will be the company's first fully integrated active pharmaceutical ingredient (API) and drug product manufacturing site dedicated to its emerging bioconjugate platform and monoclonal antibody pipeline. The facility is expected to be completed within the next five years.

2025.09.09

19:41

Eli Lilly launches TuneLab platform, opening AI drug discovery models to biotech companies

On September 9, Eli Lilly announced the launch of TuneLab, an artificial intelligence and machine learning platform that will make its AI drug discovery models, trained on years of research data, available to biotech companies. Eli Lilly stated that the AI models being released this time include proprietary data acquired at a cost of over $1 billion.

2025.09.05

08:30

Ruilong Surgery Completes US$67 Million Series D Financing, Led by Johnson & Johnson Ventures

On September 5, Ronovo Surgical announced the completion of its Series D funding round, led by Johnson & Johnson Ventures, with participation from Lilly Asia Ventures (LAV), IMCE Capital, and GraniteAsia, bringing the total raised to US$67 million. Ronovo also signed a strategic partnership agreement with Johnson & Johnson Medical Technologies. Ronovo has reportedly initiated the registration process for its laparoscopic surgical robotic system, the Haesan-1®, in Europe and South America.

2025.09.01

15:22

Novo Nordisk said Wegovy reduced heart risk by 57% compared to Eli Lilly's obesity drug.

15:08

Novo Nordisk shares rose 2.9% after its Wegovy beat Eli Lilly's Zepbound in a real-world study of heart disease.

2025.08.29

12:38

Eli Lilly and JD Health reach strategic cooperation

On August 29, Eli Lilly China announced a strategic partnership with JD Health, aiming to create innovative digital healthcare experiences for people with overweight/obesity, type 2 diabetes and alopecia areata.

2025.08.26

21:36

Eli Lilly (LLY.N) rose 4% as the company plans to apply for approval of a weight loss drug in 2025.

21:31

The three major U.S. stock indexes opened slightly lower, with Eli Lilly rising more than 3%.

The three major U.S. stock indices opened slightly lower, with the Dow Jones Industrial Average down 0.13%, the S&P 500 down 0.06%, and the Nasdaq Composite down 0.04%. Eli Lilly rose over 3% after the company's Phase 3 clinical trial of orforglipron, an oral GLP-1RA, in patients with obesity and type 2 diabetes was successful.

19:08

Eli Lilly's stock price rose 2.2% in pre-market trading.

Eli Lilly's shares rose 2.2% in premarket trading after its oral GLP-1 drug reduced weight by 10.5% in patients with type 2 diabetes in a late-stage trial.

19:01

Eli Lilly (LLY.N)'s pre-market gains in the U.S. market expanded to 2.8% at one point.

18:57

Eli Lilly (LLY.N) shares rose about 1% in pre-market trading.

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Musk: XAI will certainly raise funds in the next few months, but not now
                            2025-09-20

                                    Nvidia (NVDA.O) fell further, dropping nearly 3%.
                            2025-09-17

                                    SoftBank and OpenAI's AI joint venture in Japan is severely delayed, with an update now expected in November.
                            2025-09-18

                                    HGTECH's 3.2T NPO products are used by leading industry customers
                            2025-09-24

                                    Alipay's two operating entities have completed the name change
                            2025-09-19